Alnylam Pharmaceuticals Inc (ALNY)vsAurinia Pharmaceuticals Inc (AUPH)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
AUPH
Aurinia Pharmaceuticals Inc
$14.37
+1.13%
HEALTHCARE · Cap: $1.91B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 1212% more annual revenue ($3.71B vs $283.06M). AUPH leads profitability with a 101.5% profit margin vs 8.5%. AUPH trades at a lower P/E of 6.9x. AUPH earns a higher WallStSmart Score of 68/100 (B-).
ALNY
Hold49
out of 100
Grade: D+
AUPH
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Margin of Safety
+85.0%
Fair Value
$96.88
Current Price
$14.37
$82.51 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Attractively priced relative to earnings
Every $100 of equity generates 60 in profit
Keeps 102 of every $100 in revenue as profit
Strong operational efficiency at 55.7%
Earnings expanding 15073.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Smaller company, higher risk/reward
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : AUPH
The strongest argument for AUPH centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 101.5% and operating margin at 55.7%. Revenue growth of 28.8% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : AUPH
The primary concerns for AUPH are Market Cap, Altman Z-Score.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while AUPH is a growth play — different risk/reward profiles.
AUPH carries more volatility with a beta of 1.59 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
AUPH scores higher overall (68/100 vs 49/100), backed by strong 101.5% margins and 28.8% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Aurinia Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?